Nurix Therapeutics, Inc. NRIX 深 滬
已收盤 02-06 16:00:00 美东时间
16.85
+0.900
+5.64%
華盛通- 最 高17.03
- 今 開16.29
- 成交量 83.66万股
- 最 低 16.26
- 昨 收 15.95
- 總市值 17.33亿
- 52周最高 22.4999
- 市盈率 靜 --
- 換手率 0.81%
- 52周最低 8.18
- 委 比 52.96%
- 總股本 1.03亿
- 歷史最高 52.38
- 量 比 0.71
- 振 幅 4.83%
- 歷史最低 4.22
- 每 手 1
- 風險率 3.42%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | Meta 、IBM、拉姆研究、布林克国际等获多家机构上调目标价；微软、特斯拉、ServiceNow、自动数据处理等遭多家下调评级
今日重点评级关注：Piper Sandler：上调Korro Bio评级至"超配"，目标价从11美元升至30美元；Piper Sandler：维持Nurix Therapeutics"超配"评级，目标价从32美元升至35美元
01-30 17:38
Meta Platforms To Rally More Than 71%? Here Are 10 Top Analyst Forecasts For Thursday
Top Wall Street analysts changed their outlook on these top names. For a comple...
01-29 20:47
Needham Reiterates Buy on Nurix Therapeutics, Maintains $26 Price Target
Needham analyst Gil Blum reiterates Nurix Therapeutics (NASDAQ:NRIX) with a Buy and maintains $26 price target.
01-29 19:25
美股大行评级 | 潜在涨幅197.4%！奥麦罗制药获HC Wainwright升目标价至40美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持奥麦罗制药"买入"评级，目标价从20美元升至40美元；HC Wainwright & Co.：维持Cullinan Therapeutics"买入"评级，目标价从26美元升至27美元
01-09 20:22
Morgan Stanley Upgrades Nurix Therapeutics to Overweight, Raises Price Target to $36
Morgan Stanley analyst Terence Flynn upgrades Nurix Therapeutics (NASDAQ:NRIX) from Equal-Weight to Overweight and raises the price target from $15 to $36.
01-08 20:10
Oppenheimer’s best small and mid-cap ideas for 2026
Oppenheimer Research released a list of its best ideas for small-caps and mid-caps in the new year. Analysts said that, absent the traditional warning signs that have historically preceded market down...
01-07 00:59
Nurix Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference
Nurix Therapeutics, Inc. announced that its CEO, Arthur T. Sands, M.D., Ph.D., will present a corporate update at the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026, in San Francisco. The presentation will be available via webcast on the company's website. Nurix, focused on targeted protein degradation medicines for oncology and autoimmune diseases, has a clinical-stage pipeline including BTK degraders and CBL-B inhibitors, as ...
01-05 12:00
美股大行评级 | 潜在涨幅263.64%！Milestone Pharmaceuticals获富国银行升目标价至8美元，维持"超配"评级
今日重点评级关注：富国银行：维持Milestone Pharmaceuticals"超配"评级，目标价从4美元升至8美元；富国银行：维持Kyverna Therapeutics"超配"评级，目标价从31美元升至33美元
2025-12-17 10:46
Wells Fargo Maintains Overweight on Nurix Therapeutics, Raises Price Target to $30
Wells Fargo analyst Derek Archila maintains Nurix Therapeutics (NASDAQ:NRIX) with a Overweight and raises the price target from $21 to $30.
2025-12-16 22:59
美股大行评级 | 超配！大摩上调回声星通信评级；汽车地带、CBRL、金宝汤、家得宝等遭多家大行下调目标价
今日重点评级关注：Ascendiant Capital：维持Lucid Diagnostics"买入"评级，目标价从8美元升至8.25美元；Ascendiant Capital：维持Aytu BioPharma"买入"评级，目标价从12.5美元升至13美元
2025-12-11 10:33
